No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

被引:43
作者
Peterson, Dylan W. [1 ]
Ando, D. Michael [1 ]
Taketa, Daryl A. [1 ]
Zhou, Hongjun [2 ]
Dahlquist, Fredrick W. [2 ]
Lew, John [1 ]
机构
[1] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA
[2] Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; neurotoxicity; NMR; protein kinase; proteolysis; CYCLIN-DEPENDENT KINASE-5; DIRECTED PROTEIN-KINASE; ACTIVATOR P35; SUBSTRATE-SPECIFICITY; MOUSE MODEL; P25; ALZHEIMERS; DISEASE; SITES; NEUROFILAMENT;
D O I
10.1073/pnas.0912718107
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknown, there is common belief that CDK5/p25 is catalytically hyperactive compared to CDK5/p35. Here, we have compared the steady-state kinetic parameters of CDK5/p35 and CDK5/p25 towards both histone H1, the best known substrate for both enzymes, and the microtubule-associated protein, tau, a physiological substrate whose in vivo phosphorylation is relevant to Alzheimer's disease. We show that the kinetics of both enzymes are the same towards either substrate in vitro. Furthermore, both enzymes display virtually identical kinetics towards individual phosphorylation sites in tau monitored by NMR. We conclude that conversion of p35 to p25 does not alter the catalytic efficiency of the CDK5 catalytic subunit by using histone H1 or tau as substrates, and that neurotoxicity associated with CDK5/p25 is unlikely attributable to CDK5 hyperactivation, as measured in vitro.
引用
收藏
页码:2884 / 2889
页数:6
相关论文
共 55 条
[1]   Hyperphosphorylated tan and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 [J].
Ahlijanian, MK ;
Barrezueta, NX ;
Williams, RD ;
Jakowski, A ;
Kowsz, KP ;
McCarthy, S ;
Coskran, T ;
Carlo, A ;
Seymour, PA ;
Burkhardt, JE ;
Nelson, RB ;
McNeish, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2910-2915
[2]   Defining Cdk5 ligand chemical space with small molecule inhibitors of Tau phosphorylation [J].
Ahn, JS ;
Radhakrishnan, ML ;
Mapelli, M ;
Choi, S ;
Tidor, B ;
Cuny, GD ;
Musacchio, A ;
Yeh, LA ;
Kosik, KS .
CHEMISTRY & BIOLOGY, 2005, 12 (07) :811-823
[3]  
Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO
[4]  
2-6
[5]   Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules [J].
Amniai, Laziza ;
Barbier, Pascale ;
Sillen, Alain ;
Wieruszeski, Jean-Michel ;
Peyrot, Vincent ;
Lippens, Guy ;
Landrieu, Isabelle .
FASEB JOURNAL, 2009, 23 (04) :1146-1152
[6]   ABNORMAL ALZHEIMER-LIKE PHOSPHORYLATION OF TAU-PROTEIN BY CYCLIN-DEPENDENT KINASES CDK2 AND CDK5 [J].
BAUMANN, K ;
MANDELKOW, EM ;
BIERNAT, J ;
PIWNICAWORMS, H ;
MANDELKOW, E .
FEBS LETTERS, 1993, 336 (03) :417-424
[7]  
BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825
[8]  
Cornish-Bowden A., 1995, Fundamentals of Enzyme Kinetics
[9]   A Jekyll and Hyde disease: roles for Cdk5 in brain development and disease [J].
Cruz, JC ;
Tsai, LH .
CURRENT OPINION IN NEUROBIOLOGY, 2004, 14 (03) :390-394
[10]   NMRPIPE - A MULTIDIMENSIONAL SPECTRAL PROCESSING SYSTEM BASED ON UNIX PIPES [J].
DELAGLIO, F ;
GRZESIEK, S ;
VUISTER, GW ;
ZHU, G ;
PFEIFER, J ;
BAX, A .
JOURNAL OF BIOMOLECULAR NMR, 1995, 6 (03) :277-293